SENEX BIOTECHNOLOGY

Senex Biotechnology, Inc. engages in discovering and developing therapeutic agents to treat cancer, viral diseases, and age-related diseases. The company offers SNX2 non-cytotoxic molecules compounds that are developed against viral diseases, age-associated diseases, and as add-ons to existing anticancer drug regimens; and SNX9 cyclin-dependent kinase inhibitor pathway inhibitors that are developed for cancer treatment. It offers therapeutic agents to treat cancer and a range of diseases associated with the aging process, such as Alzheimer’s disease, renal disease, atherosclerosis, and arthritis. The company was incorporated in 2002 and is based in Columbia, South Carolina.